U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Development Resources
  5. Cefepime – Injection products
  1. Development Resources

Cefepime – Injection products

 

Minimum Inhibitory
Concentrations
(mcg/mL)

Disk Diffusion
(zone diameter in mm)

Pathogen

S

SDD

I

R

S

SDD

I

R

Enterobacteralesa

M100 standard is recognized

M100 standard is recognized

Pseudomonas aeruginosa b

≤8

-

-

≥16

≥18

-

-

≤17

Streptococcus pneumoniae
(non-meningitis)

M100 standard is recognized

-

-

-

-

Streptococcus spp β- Hemolytic Group

M100 standard is recognized

Streptococcus spp Viridans Group

M100 standard is recognized

S = Susceptible; SDD= susceptible-dose dependent; I = Intermediate; R = Resistant
a For isolates of Enterobacterales with SDD susceptibility, use a dose of 2g every 8 hours in patients with normal renal function.
b For Pseudomonas aeruginosa, use a dose of 2 g IV every 8 hours in patients with normal renal function.

Exceptions to the recognized standard of CLSI M100

For the bacteria listed below, susceptibility test interpretive criteria are not recognized at this time:

Acinetobacter spp

Other Non-Enterobacterales

Haemophilus influenzae and Haemophilus parainfluenzae

Neisseria gonorrhoeae

Back to Top